Hemoderivative Market Report: Trends, Forecast and Competitive Analysis to 2031

Hemoderivative Market Trends and Forecast

The future of the global hemoderivative market looks promising with opportunities in the therapeutic and excipient markets. The global hemoderivative market is expected to grow with a CAGR of 6.5% from 2025 to 2031. The major drivers for this market are the increasing demand for blood products, the rising prevalence of chronic diseases, and the growing advancements in biotechnology.

• Lucintel forecasts that, within the type category, immunoglobulin is expected to witness the highest growth over the forecast period.

• Within the application category, therapeutic is expected to witness higher growth.

• In terms of region, North America is expected to witness the highest growth over the forecast period. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Hemoderivative Market

The hemoderivative market is witnessing a tremendous revolution propelled by technological advancements, shifts in healthcare trends, and changing patient demands.

• Rising Demand for Immunoglobulins: The therapeutic uses of immunoglobulins are extending beyond primary immunodeficiency to cover neurological conditions, autoimmune diseases, and infectious diseases. With a larger scope, combined with enhanced diagnostics, comes a tremendous surge in demand worldwide. The effect is substantial, exerting pressure on plasma supply and spurring research into alternative sources and improved production processes to keep up with the increasing clinical demands.

• Advances in Recombinant Hemoderivatives: Technological advancements in genetic engineering are giving rise to the creation and greater use of recombinant substitutes for some plasma-derived products, including coagulation factors. The recombinant products potentially have benefits in safety, assurance of supply, and lower risk of pathogen transmission. Their increased availability is affecting the market by offering substitutes for conventional plasma-derived products and encouraging competition.

• Personalized Medicine Strategies: Increasingly, there is a move towards using hemoderivatives in accordance with each patient‘s characteristics and particular disease subtypes. Improved diagnostics and greater knowledge of disease mechanisms are allowing more effective and targeted treatments using plasma-derived products. This strategy is impacting the market by calling for more specialized products and possibly smaller batches, necessitating increased flexibility in manufacturing.

• Focus on Efficiency and Safety of Plasma Collection: A high and safe availability of plasma supply is a top priority for the hemoderivative market. Advances in recent trends involve the use of state-of-the-art screening technology on donors and donated plasma, as well as plasma collection process optimization to achieve maximum yield at minimal costs. These steps are important for sustaining the market‘s sustainability as well as ensuring public confidence in the plasma-derived therapies‘ safety.

• Home-Based Infusion Therapies Development: To enhance patient quality of life and convenience, attention has shifted toward developing products of hemoderivatives that can be administered subcutaneously or at home. It is most relevant for patients who need chronic replacement therapies, for example, primary immunodeficiencies or hemophilia patients. Having more convenient administration routes is improving patient compliance and offering larger market spaces for these therapies. These trends are remodeling the hemoderivative market by propelling product development innovation, impacting plasma collection strategy, and enhancing patient convenience and access. The market is increasingly diverse with the entry of recombinant products and targeted treatment strategies, but the core requirement for a safe and adequate supply of plasma continues to be an important consideration.

Recent Development in the Hemoderivative Market

The market for hemoderivatives is defined by constant attempts at increasing product safety, broadening therapeutic use, and guaranteeing a secure supply to cover increasing worldwide demand.

• Application of Advanced Pathogen Reduction Technologies: Over the past few years, usage of advanced technologies to inactivate or remove pathogens from donated plasma has gained widespread acceptance. These technologies, such as photochemical treatment and nanofiltration, not only advance the safety profile of plasma-derived products but also decrease the risk of transfusion-transmitted infections and improve trust in these therapies.

• Widening of Therapeutic Uses for Established Hemoderivatives: New clinical uses are being discovered for established plasma-derived products, including immunoglobulins and albumin. For example, the indications of immunoglobulins are growing as they are being used to treat more types of autoimmune and neurological diseases. These widened indications are propelling market expansion and demonstrating the all-round applicability of hemoderivatives in meeting various medical requirements.

• Novel Plasma Fractionation Technologies: New plasma fractionation technologies seek to enhance the yield and quality of individual plasma proteins and lower production costs. Novel chromatographic techniques and membrane filtration methods are being investigated to increase the effectiveness of isolating valuable products from plasma to provide a more sustainable and cost-efficient production of hemoderivatives.

• Expanded Emphasis on Biosimilar Production for Plasma-Derived Therapies: Whereas authentic biosimilars are more prevalent for recombinant biologics, there is expanding interest in producing follow-on biologics or biosimilar-type products for some hemoderivatives, especially in countries with cost-containment healthcare systems. Such a trend is geared towards expanding patient access to life-sustaining therapies through providing cheaper substitutes for branded products.

• Development of National Plasma Collection Programs in Developing Nations: In order to minimize dependence on plasma imports and increase self-sufficiency, a number of developing countries are investing in the establishment of national plasma collection facilities. This includes the installation of plasma donation centers, ensuring quality control procedures, and the training of staff for ensuring the safety and quality supply of plasma for the local production of hemoderivatives. These advances are having a dramatic effect on the hemoderivative marketplace by enhancing the safety and accessibility of these life-saving therapies. Improvements in pathogen reduction and fractionation technology are increasing product quality and manufacturing efficiency, while therapeutic indication expansion and the availability of biosimilar alternatives are enhancing patient access. National plasma program development in emerging nations is helping to enhance world self-sufficiency in hemoderivative supply.

Strategic Growth Opportunities in the Hemoderivative Market

The hemoderivative market offers multiple strategic growth opportunities fueled by the distinctive therapeutic benefit of plasma proteins across various medical applications.

• Treatment of Primary and Secondary Immunodeficiencies: Rising diagnosis and recognition of primary immunodeficiency disorders, combined with increasing incidences of secondary immunodeficiencies caused by such conditions as HIV infection or chemotherapy, offer a tremendous growth opportunity for immunoglobulin therapy. Expanding newborn screening programs and enhancing diagnostic technology will continue to stimulate demand for these life-saving interventions.

• Treatment of Autoimmune and Neurological Diseases: The therapeutic uses of intravenous and subcutaneous immunoglobulins in the treatment of an increasingly long list of autoimmune and neurological diseases, including Guillain-Barré syndrome, CIDP, and myasthenia gravis, present tremendous market growth opportunities. Continued research into new indications and improved dosing regimens will continue to stimulate this growth.

• Critical Care and Surgery Support: Albumin, being a leading hemoderivative, is an essential component of fluid resuscitation and oncotic pressure maintenance in critically ill patients such as those who have experienced severe burns, trauma, or major surgery. The rising rate of complicated surgical cases and the importance of successful supportive therapy in emergency medicine ensure a regular and increasing need for albumin solutions.

• Hemophilia and Other Bleeding Disorder Treatment: Plasma-derived and recombinant coagulation factors are necessary to prevent and treat bleeding events in hemophilia A and B patients and other rare bleeding disorders. Advances in longer-acting recombinant factors and the growing emphasis on prophylactic treatment regimens provide opportunities for future market expansion and enhanced patient outcomes.

• Alpha-1 Antitrypsin Deficiency Therapy: Alpha-1 antitrypsin deficiency is a genetic disorder that may result in lung disease and liver disease. Augmentation therapy with plasma-derived AAT is the mainstay treatment, and enhanced awareness and diagnosis of this underdiagnosed condition are a growth opportunity for AAT products. Newborn screening programs in certain areas are also leading to earlier diagnosis and initiation of treatment. These strategic development opportunities are influencing the hemoderivative market by compelling research and development activity aimed at broadening indications, enhancing product formulations, and developing diagnostic capabilities. Growing appreciation of the pivotal contribution of hemoderivatives to the treatment of a broad spectrum of acute and chronic conditions will continue to drive sustained market growth in these major areas of application.

Hemoderivative Market Driver and Challenges

The hemoderivative market is shaped by a constantly changing interaction of many different technological, economic, and regulatory influences that are both growth catalysts and likely to constrain growth. The factors responsible for driving the hemoderivative market include: 1. Increasing Prevalence of Target Disease: Increasing rates of chronic diseases, autoimmune disorders, bleeding disorders, and primary immunodeficiencies worldwide are a key driving factor for the hemoderivative market. Aging population, lifestyle changes, and enhanced diagnostic efficiency lead to a growing patient base demanding plasma-derived therapies, thus driving demand. 2. Therapeutic Expansion: Continuous clinical trials and research are continually determining novel therapeutic indications for the currently available hemoderivatives, like immunoglobulins in autoimmune diseases and neurological disorders. The expanding therapeutic indications widen the pool of potential patients and fuel growth in the market beyond conventional indications. 3. Fractionation and Manufacturing Technological Advances: Advances in fractionation technology are enhancing the purity and yield of individual plasma proteins, contributing to improved manufacturing processes and lower costs. Advances in manufacturing technologies are also improving the quality and safety of hemoderivatives, making them more effective and reliable. 4. Rising Healthcare Spending and Access: Increased healthcare spending in most regions of the globe, along with enhanced access to medical treatment, enables more patients to be treated with hemoderivatives. Expansion of government programs and insurance coverages is also key in making such treatments widely available. 5. Rising Diagnosis and Awareness of Rare Diseases: Rising awareness on the part of healthcare providers and the general public regarding rare diseases, numerous which are managed using hemoderivatives, is translating into earlier and more correct diagnoses. This enhanced identification of patients suffering from primary immunodeficiencies and alpha-1 antitrypsin deficiency accounts for increased rates of treatment and growth in the market. Challenges in the hemoderivative market are: 1. Plasma Supply Constraints: The production of hemoderivatives is entirely dependent on the availability of donated human plasma. Ensuring a sufficient supply of high-quality plasma to meet the growing demand is a significant and ongoing challenge. Factors such as donor availability, collection costs, and regulatory restrictions on plasma donation can impact the supply chain. 2. High Manufacturing Costs: The sophisticated processes of plasma fractionation, purification, and viral inactivation add to the high cost of producing hemoderivatives. These cost factors may restrict patient access, especially in cost-sensitive markets, and cause healthcare budgets to be strained. 3. Regulatory Divergences and Complexities: Hemoderivative regulations differ markedly between and even within regions. Divergent and complex approval, quality control, and safety testing requirements may serve as obstacles to market access and drive up the cost and time of new product launch to patients worldwide. The net effect of these drivers and issues on the hemoderivative market is one of potential for rapid growth moderated by the intrinsic constraints of a biological raw material and the intricacies of its production and regulation. As with the strength of rising disease incidence, broadening applications, and advancing technologies being strong growth drivers, challenges such as plasma supply, cost of production, and regulatory barriers demand constant innovation and strategic planning to make these life-saving treatments broadly available.

List of Hemoderivative Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies hemoderivative companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the hemoderivative companies profiled in this report include-

• Grifols

• CSL

• Takeda

• Octapharma

• CBPO

• Hualan Bio

• Kedrion

• Shanghai RAAS

• LFB Group

• Weiguang Bio

Hemoderivative Market by Segment

The study includes a forecast for the global hemoderivative market by type, application, and region.

Hemoderivative Market by Type [Value from 2019 to 2031]:

• Albumin

• Immunoglobulins

• Coagulation Factors

• Others

Hemoderivative Market by Application [Value from 2019 to 2031]:

• Therapeutics

• Excipient

• Others

Hemoderivative Market by Region [Value from 2019 to 2031]:

• North America

• Europe

• Asia Pacific

• The Rest of the World

Country Wise Outlook for the Hemoderivative Market

Current trends in the market for hemoderivatives are dominated by a sustained push for innovation, improved safety, and widening therapeutic use. These plasma-derived drugs, essential for the treatment of many rare and chronic diseases, are seeing growing demand worldwide as a result of an aging population and advances in diagnostics. Regulatory environments are adapting to balance patient safety with market access. At the same time, producers are concentrating on optimizing plasma fractionation and collection processes to achieve better yields and lower costs. The creation of recombinant substitutes and biosimilars also adds a dynamic element to this market.

• United States: The United States, being a large consumer of hemoderivatives, is experiencing high emphasis on plasma collection safety, as well as efficiency. Regulatory authorities such as the FDA are making constant changes to guidelines to ensure plasma-derived products are of high quality and safe. There is also increasing interest in finding new uses for current hemoderivatives and bringing recombinant substitutes for some factors into the market. In addition, the industry has major players on a global level and has a well-developed system of plasma donation and processing.

• China: The Chinese hemoderivative market is also growing at a high pace, fueled by rising healthcare spending and awareness of rare diseases. The government of China is actively encouraging the development of the local plasma fractionation business with a view to lessening its dependence on imports. Recent trends have seen local players consolidating and the imposition of stricter regulatory norms to improve product quality and safety. There is also an increasing need for a greater variety of hemoderivatives to meet the demands of its extensive population.

• Germany: Germany possesses an advanced healthcare system and high demand for hemoderivatives. Developments in recent times have been directed at maximizing the use of plasma resources as well as guaranteeing a reliable supply of priority products. German regulatory policy, as with the European Union, prioritizes high quality and safety standards. There is also constant research and development in new fractionation technology as well as novel therapeutic uses of plasma proteins.

• India: India‘s hemoderivative market remains in a relatively early stage but is exhibiting strong growth potential. Growing access to healthcare and increasing prevalence of blood disorders are fueling demand. Recent activity includes initiatives to develop a strong domestic plasma collection and fractionation infrastructure. The regulatory environment is shifting to promote local production while maintaining product safety and efficacy. Partnerships with global players and technology transfers are also becoming more prevalent.

• Japan: Japan boasts a highly developed healthcare system and a high demand for high-quality hemoderivatives, notably for its elderly population. Recent trends include the emphasis on the assurance of plasma product supply stability and streamlining the domestic fractionation industry. Regulatory bodies are strict in maintaining product quality and safety standards. There is also a focus on investigating recombinant alternatives and novel therapeutic uses of plasma proteins.

Features of the Global Hemoderivative Market

Market Size Estimates: Hemoderivative market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions. Segmentation Analysis: Hemoderivative market size by type, application, and region in terms of value ($B). Regional Analysis: Hemoderivative market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the hemoderivative market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the hemoderivative market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the growth forecast for hemoderivative market? Answer: The global hemoderivative market is expected to grow with a CAGR of 6.5% from 2025 to 2031. Q2. What are the major drivers influencing the growth of the hemoderivative market? Answer: The major drivers for this market are the increasing demand for blood products, the rising prevalence of chronic diseases, and the growing advancements in biotechnology. Q3. What are the major segments for hemoderivative market? Answer: The future of the hemoderivative market looks promising with opportunities in the therapeutic and excipient markets. Q4. Who are the key hemoderivative market companies? Answer: Some of the key hemoderivative companies are as follows:

• Grifols

• CSL

• Takeda

• Octapharma

• CBPO

• Hualan Bio

• Kedrion

• Shanghai RAAS

• LFB Group

• Weiguang Bio Q5. Which hemoderivative market segment will be the largest in future? Answer: Lucintel forecasts that, within the type category, immunoglobulin is expected to witness the highest growth over the forecast period. Q6. In hemoderivative market, which region is expected to be the largest in next 5 years? Answer: In terms of region, North America is expected to witness the highest growth over the forecast period. Q7. Do we receive customization in this report? Answer: Yes, Lucintel provides 10% customization without any additional cost.